M. Keating

Publications1,390
h-index136
Citations80,179
Highly Influential Citations2,647
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Kantarjian
  • 4,797 Publications • 223,246 Citations
  • S. O'brien
  • 1,863 Publications • 88,482 Citations
  • W. Wierda
  • 1,210 Publications • 47,619 Citations
  • A. Ferrajoli
  • 764 Publications • 22,045 Citations
  • Publications
  • Influence
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
TLDR
Detailed deletion and expression analysis shows that miR15 and miR16 are located within a 30-kb region of loss in CLL, and that both genes are deleted or down-regulated in the majority (≈68%) of CLL cases.
View on Publisher
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
TLDR
These revisions evolved as the guidelines were used in a systematic fashion in large clinical trials and with the experience following the use of newer, more effective agents, such as fludarabine.
View on PubMed
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working…
TLDR
The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided.
View on PubMed
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
TLDR
Although the presence of an unmutated IgV(H) gene is strongly associated with the expression of Zap-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.
View on PubMed
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
TLDR
Alemtuzumab induced significant responses in patients with relapsed or refractory B-cell chronic lymphocytic leukemia with clinical benefit in the majority and with acceptable toxicity in a high-risk group.
View on PubMed
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
TLDR
The results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.
View on PubMed
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
TLDR
Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.
View on PubMed
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
TLDR
FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy.
View on PubMed
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
TLDR
Recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.
View on PubMed
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
TLDR
According to the experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL.
View on PubMed
...
...